# Effectiveness and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney) Essence Deficiency

> **NCT07270146** · PHASE4 · COMPLETED · sponsor: **DongE E Jiao Coporation Limited** · enrollment: 360 (actual)

## Conditions studied

- Mild and Moderate Oligozoospermia Asthenospermia or Oligoasthenospermia and the Syndrome Differentiation Type is Shen (Kidney) Essence Deficiency

## Interventions

- **DRUG:** Guilu Erxian Oral Liquid
- **DRUG:** Wuzi Yanzong oral liquid

## Key facts

- **NCT ID:** NCT07270146
- **Lead sponsor:** DongE E Jiao Coporation Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-08
- **Primary completion:** 2025-02-10
- **Final completion:** 2025-02-10
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07270146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07270146, "Effectiveness and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney) Essence Deficiency". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07270146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*